SECOND AMENDMENT TO MASTER PURCHASE AGREEMENTMaster Purchase Agreement • July 13th, 2016 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Second Amendment (this “Amendment”) to the Master Purchase Agreement dated as of July 26, 2015, as amended on June 9, 2016 (the “Agreement”), by and between Teva Pharmaceutical Industries Ltd., a company organized under the laws of Israel (“Buyer Parent”), and Allergan plc, a public company limited by shares organized under the laws of Ireland (“Seller Parent”), is dated as of July 5, 2016.
THIRD AMENDMENT TO MASTER PURCHASE AGREEMENTMaster Purchase Agreement • July 13th, 2016 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Third Amendment (this “Amendment”) to the Master Purchase Agreement dated as of July 26, 2015, as amended on June 9, 2016 and July 5, 2016 (the “Agreement”), by and between Teva Pharmaceutical Industries Ltd., a company organized under the laws of Israel (“Buyer Parent”), and Allergan plc, a public company limited by shares organized under the laws of Ireland (“Seller Parent”), is dated as of July 11, 2016.
FIRST AMENDMENT TO MASTER PURCHASE AGREEMENTMaster Purchase Agreement • July 13th, 2016 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This First Amendment (this “Amendment”) to the Master Purchase Agreement (the “Agreement”) dated as of July 26, 2015, by and between Teva Pharmaceutical Industries Ltd., a company organized under the laws of Israel (“Buyer Parent”), and Allergan plc, a public company limited by shares organized under the laws of Ireland (“Seller Parent”), is dated as of June 9, 2016.
ALLERGAN LETTERHEAD]Master Purchase Agreement • July 13th, 2016 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
